DSE Analyst data: 2026-07-13

PHARMAID

Pharma Aids Limited · Pharmaceuticals and Chemicals · Cat A
44/100
Mixed
৳616.4

DSE Hexagon

Stands out for a strong earnings record and constructive price action, held back by looks fully priced.

Value4Financial Health60Dividend6Quality83Momentum72Integrity50

Six lenses, each scored 0–100 from the analysis. Integrity is DSE-specific — it reads how organic the price action is (high = clean, low = concentrated-operator risk). Descriptive only, not a recommendation.

Risks & rewards

Risks (0)

No notable risk flags.

Rewards (1)

  • ✓ Earnings trending up

Score breakdown

Price history & performance

52-week high৳664.6
52-week low৳467.0
From 52w high-7.3%
Beta0.86
7D +3.2%
1M +8.1%
3M +14.2%
6M +25.7%
1Y +15.5%
YTD +26.3%

Shareholder returns vs DSEX

PHARMAID+6.3%
DSEX+2.4%

PHARMAID outperformed the DSEX since Jul 8, 2026 — that's when we started tracking the index, so this window will get longer over time.

Volatility

Annualized volatility34.4%
Daily VaR (95%)-2.93%
Max drawdown (5y)-51.9%
Correlation to market0.53

Typical volatility for a DSE stock. Descriptive only — past volatility is not a forecast.

Technical read

RSI (14)68.7
MACDbullish
Bollingerabove upper band
Price cycle (Wyckoff)MARKUP
Health trendstable
Flow pressureaccumulation

Valuation

Fair value368.1 (257.7-478.5)
Upside-40.00%
Dividend yield+0.50%
Fundamental verdictWATCH
ConfidenceLOW (re-rate ceiling, not target)

Ownership

Institutional holding24.21%
Foreign holding0.0%
Free float56.4%

Sponsor, institutional, foreign and public holdings from the latest disclosed shareholding pattern. Descriptive only.

Share structure

Authorized capital৳50mn
Paid-up capital৳31.2mn
Face value৳10
Market lot1
Outstanding shares3,120,000
Last AGM24-12-2025
Fiscal year end30-Jun
Reserve & surplus (ex-OCI)৳401.2mn
Other comprehensive income৳0mn

Financials

Recent P/E ratio

DateCurrent P/ETrailing P/E
Jul 14, 2026 22.85 24.74
Jul 13, 2026 22.89 24.77
Jul 12, 2026 22.03 23.85
Jul 9, 2026 21.62 23.4
Jul 8, 2026 21.53 23.31
Jul 7, 2026 21.51 23.28

Based on the latest un-audited financial statements. Descriptive only.

Dividend history

202530%
202425%
202310%
202250%
202150%
202050%
201950%
201850%
201735%
201630%
201525%

Earnings & NAV

YearEPSNAVDividend
2025 20.45 138.58 30%
2024 19.61 109.89 25%
2023 -2.05 91.28 10%
2022 11.14 98.83 50%

Quarterly EPS — FY2026

Q16.81
Q27.28
Half-year14.09
Q36.11
Nine-month20.2

From disclosed annual reports and dividend declarations. Descriptive only, not a forecast.

Levels

Resistance

৳617.5
৳644
৳665
৳689

Support

৳609.9
৳590
৳570.1
৳552.2

Historical bounce zones

Mar 5, 2025: ৳515→৳593.9 +15%
May 27, 2025: ৳454→৳563 +24%
Jun 23, 2025: ৳500.2→৳644 +29%
Jul 29, 2025: ৳585.1→৳677.8 +16%
Oct 22, 2025: ৳500.1→৳615 +23%
Nov 13, 2025: ৳452.7→৳580 +28%
Dec 28, 2025: ৳470→৳615 +31%
Mar 8, 2026: ৳515→৳625.4 +21%

Sector peers

Other Pharmaceuticals and Chemicals names, ranked by our analysis score (DSE has no market-cap feed). Descriptive comparison only.

Historical outlook

Based on how similar setups behaved historically — not a prediction of what will happen.

10-day 40% vs 40% market avg Typical move: -6.2% / -1.3% / 5.5%
30-day 31% vs 42% market avg Typical move: -10.4% / -2.4% / 8.7%

Signals: RSI>70 overbought|Above upper Bollinger|Stochastic>80

Reference levels

Descriptive reference points from the analysis — not instructions to buy or sell.

Entry readWAIT (until clears both axes)
Reference stopn/a
Reference target
Timing notewatch; no fresh money

Elevated (score 123) — acceptable only with real earnings and sponsor backing; artificial-activity lens applies. Phase: ACCUMULATION (12% >200-MA, flow ACC). ⚠ Balance sheet DETERIORATING (Altman Z falling) — early warning. [fundamentals WATCH, payout 15.0%, yield 0.5%]

My notes

Educational market analysis for the Dhaka Stock Exchange. Descriptive information only — not investment advice, not a buy/sell recommendation, and not from a licensed advisor. Prices and analysis can be delayed or wrong; verify with your broker before acting.